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Abstract 
The flesh-eating bacterium group A Streptococcus (GAS) binds and activates human plasminogen, 
promoting invasive disease. Streptococcal surface enolase (SEN), a glycolytic pathway enzyme, is an 
identified plasminogen receptor of GAS. Here we used mass spectrometry (MS) to confirm that GAS SEN 
is octameric, thereby validating in silico modeling based on the crystal structure of S. pneumoniae -
enolase. Site-directed mutagenesis of surface-located lysine residues (SENK252+255A, SENK304A, 
SENK334A, SENK344E, SENK435L and SEN434-435) was used to examine their roles in maintaining 
structural integrity, enzymatic function and plasminogen binding. Structural integrity of the GAS SEN 
octamer was retained for all mutants except SENK344E, as determined by circular dichroism 
spectroscopy and MS. However, ion-mobility MS revealed distinct differences in the stability of several 
mutant octamers in comparison to wild-type. Enzymatic analysis indicated that SENK344E had lost -
enolase activity, which was also reduced in SENK334A and SENΔ434-435. Surface plasmon resonance 
demonstrated that the capacity to bind human plasminogen was abolished in SENK252+255A, SENK435L 
and SENΔ434-435. The lysine residues at positions 252, 255, 434 and 435, therefore play a concerted role 
in plasminogen acquisition. This study demonstrates the ability of combining in silico structural modeling 
with ion mobility-MS validation for undertaking functional studies on complex protein structures. 
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The flesh-eating bacterium group A 
Streptococcus (GAS) binds and activates human 
plasminogen, promoting invasive disease. 
Streptococcal surface enolase (SEN), a 
glycolytic pathway enzyme, is an identified 
plasminogen receptor of GAS. Here we used 
mass spectrometry (MS) to confirm that GAS 
SEN is octameric, thereby validating in silico 
modeling based on the crystal structure of S. 
pneumoniae α-enolase. Site-directed 
mutagenesis of surface-located lysine residues 
(SENK252+255A, SENK304A, SENK334A, SENK344E, 
SENK435L and SENΔ434-435) was used to examine 
their roles in maintaining structural integrity, 
enzymatic function and plasminogen binding. 
Structural integrity of the GAS SEN octamer 
was retained for all mutants except SENK344E, as 
determined by circular dichroism spectroscopy 
and MS. However, ion-mobility MS revealed 
distinct differences in the stability of several 
mutant octamers in comparison to wild-type. 
Enzymatic analysis indicated that SENK344E had 
lost α-enolase activity, which was also reduced 
in SENK334A and SENΔ434-435. Surface plasmon 
resonance demonstrated that the capacity to 
bind human plasminogen was abolished in 
SENK252+255A, SENK435L and SENΔ434-435. The 
lysine residues at positions 252, 255, 434 and 
435, therefore play a concerted role in 
plasminogen acquisition.  This study 
demonstrates the ability of combining in silico 
structural modeling with ion mobility-MS 
validation for undertaking functional studies on 
complex protein structures.   
 
Streptococcus pyogenes (group A 
Streptococcus, GAS) is a common bacterial 
pathogen, causing over 700 million human disease 
episodes each year (1). These range from serious 
life-threatening invasive diseases including 
necrotizing fasciitis and streptococcal toxic shock-
like syndrome to non-invasive infections like 
pharangytis and pyoderma.  Invasive disease, in 
combination with post-infection immune sequelae 
including rheumatic heart disease and acute post-
streptococcal glomerulonephritis, account for over 
half a million deaths each year (1). While a 
resurgence of GAS invasive infections has 
occurred in western countries since the mid-1980s, 
disease burden is much greater in developing 
countries and indigenous populations of developed 
nations, where GAS infections are endemic (2-4).  
GAS is able to bind human plasminogen 
and activate the captured zymogen to the serine 
protease plasmin (5-17). The capacity of GAS to 
do this plays a critical role in virulence and 
invasive disease initiation (3,17-19). The 
plasminogen activation system in humans is an 
important and highly regulated process that is 
responsible for breakdown of extracellular matrix 
components, dissolution of blood clots, and cell 
migration (20,21).  Plasminogen is a 92 kDa 
zymogen that circulates in human plasma at a 
 1
concentration of 2 μM (22). It consists of a binding 
region of five homologous triple loop kringle 
domains and an N-terminal serine protease domain 
that flank the Arg561-Val562 site (23) where it is 
cleaved by tissue (tPA) and urokinase plasminogen 
activator (uPA) to yield the active protease plasmin 
(20,23). GAS also has the ability to activate human 
plasminogen by secreting the virulence 
determinant streptokinase. Streptokinase forms 
stable complexes with plasminogen or plasmin, 
both of which exhibit plasmin activity (20,24). 
Activation of plasminogen by the plasmin(ogen)-
streptokinase complex circumvents regulation by 
the host plasminogen activation inhibitors, α2-
antiplasmin and α2-macroglobulin (11,20). GAS 
can bind the plasmin(ogen)-streptokinase complex 
and/or plasmin(ogen) directly via plasmin(ogen) 
receptors at the bacterial cell surface (6). These 
receptors include the plasminogen-binding group 
A streptococcal M-like protein (PAM) (25), the 
PAM related protein (Prp) (19), glyceraldehyde-3-
phosphate dehydrogenase (GAPDH; also known as 
streptococcal plasmin receptor, Plr, or 
streptococcal surface dehydrogenase, SDH) (9,26), 
and streptococcal surface enolase (SEN or α-
enolase) (27). Interactions with these GAS 
receptors occurs via lysine binding sites within the 
kringle domains of plasminogen (6). 
   In addition to its ability to bind human 
plasminogen, SEN is primarily the glycolytic 
enzyme that converts 2-phosphoglycerate to 
phosphoenolpyruvate (27-29). SEN is abundantly 
expressed in the cytosol of most bacterial species, 
but has also been identified as a surface-located 
protein in GAS and other bacteria including 
pneumococci, despite lacking classical cell surface 
protein motifs such as a signal sequence, 
membrane-spanning domain or cell-wall anchor 
motif (27,28,30,31). The interaction between SEN 
and plasminogen is reported to be facilitated by the 
two carboxyl-terminal lysine residues at positions 
434 and 435 (27,32). In contrast, an internal 
binding motif containing lysines at positions 252 
and 255 in the closely related α-enolase of 
Streptococcus pneumoniae has been shown to play 
a pivotal role in the acquisition of plasminogen in 
this bacterial species (33). The octameric  
pneumococcal α-enolase structure consists of a 
tetramer of dimers. Hence potential binding sites 
could be buried in the interface between subunits. 
In fact, the crystal structure of S. pneumoniae α-
enolase revealed that the two carboxyl-terminal 
lysine residues are significantly less exposed than 
the internal plasminogen binding motif (34).  
In this study we constructed an in silico 
model of GAS SEN, based on the pneumococcal 
octameric α-enolase crystal structure, and validated 
this model using ion mobility (IM) mass 
spectrometry (MS). Site-directed mutagenesis 
followed by structural and functional analyses 
revealed that Lys344 plays a crucial role in 
structural integrity and enzymatic function. 
Furthermore, we demonstrate that the plasminogen 
binding motif residues Lys252 and Lys255 and the 
C-terminal Lys434 and Lys435 residues are 
located adjacently in the GAS SEN structure and 




Site-directed Mutagenesis - The 
pET14bSEN expression vector encoding an N-
terminal His6-tagged SEN cloned from the M6 
GAS strain D471 (32) was used to construct site 
directed mutants. Mutants SENK435L and SENΔ434-
435 were as previously described (32). Lysine 
residues of interest within SEN were substituted 
with either alanine or glutamic acid by 
QuikChange® XL site directed mutagenesis 
(Stratagene), using primers listed in supplemental 
table S1 and methods previously described (8). 
DNA sequence analysis was used to confirm 
introduced mutations using primers given in 
supplemental table S1, and sequence reactions 
were performed using terminator ready reaction 
mix (PE Applied Biosystems) and methods 
described elsewhere (8). Samples were 
electrophoresed using an Applied Biosystems 
3130xl genetic analyzer (Applied Biosystems) and 
sequence data were analyzed using Applied 
Biosystems DNA sequencing analysis software v 
5.2 (Applied Biosystems).  
Protein Expression and Purification - 
pET14bSEN and SEN mutant constructs were 
transformed into competent E. coli BL21 STAR 
(DE3) cells and grown in LB medium 
supplemented with 100 μg ml-1 ampicillin at 37°C 
to an absorbance at 600 nm of 0.6. Expression was 
conducted as previously described (35). The pure 
proteins were dialyzed into PBS and protein 
concentration was determined using a 
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bicinchoninic acid protein assay kit (Sigma 
Aldrich).  
Nanoelectrospray-Ionization Mass 
Spectrometry (ESI-MS) - Mass spectra were 
acquired on a Waters Q-ToF Ultima mass 
spectrometer which had been modified for high 
mass operation (36) using a nanoESI source. 2 μl 
of a solution of each protein in 200 mM NH4OAc 
(concentrations ranged from 3 μM to 8 μM, as 
monomer) were electrosprayed from gold-coated 
glass capillaries prepared in-house. Q-ToF 
instrument conditions included a capillary potential 
of 1.5 kV, cone: 140 V, rf lens1: 80 V, collision 
cell: 4 V, transport and aperture: 5 V and the MCP 
detector set to 1750 V. Collision cell gas pressure 
was adjusted to 3x10-2 mbar, to provide sufficient 
collisional cooling to preserve non-covalent 
interactions and maintain the proteins in their 
native conformation. All spectra were externally 
calibrated using a CsI spectrum and reference file 
and processed using MassLynx™ software. 
Ion Mobility-Mass Spectrometry (IM-MS) 
- Ion-mobility mass spectrometry was performed 
on a Synapt HDMS system (Waters) (37), fitted 
with a 32,000 m/z quadrupole. Nanoelectrospray 
spectra were acquired using previously described 
protocols (38). The following voltages were used: 
capillary 1.65 kV, sample cone 40 V, ‘trap 
collision energy’ 10 V, ‘transfer collision energy’ 
10V, and a 0-30 V wave-height ramp in the drift 
cell. The gases used were nitrogen and argon in the 
T-Wave IM separator and collision cells, 
respectively. The pressures in the various stages 
were the following: backing 4.5 mbar, trap 6.2×10-
2 mbar, IMS 0.44 mbar, and ToF 1.6×10-6 mbar. 
Data were processed using MassLynx software, 
and the MS dimension was calibrated externally. 
All spectra are shown here with minimal 
smoothing, linear intensity scales, and no 
background subtraction. The collision cross-
section for wild-type protein was measured using a 
previously described approach (39).  
In Silico Modeling - Sequence searches 
using BLAST (40) identified α-enolase from S. 
pneumoniae as the protein with a known three-
dimensional structure most closely related to GAS 
SEN (93% identity at the amino-acid level). The 
octameric biological unit of S. pneumoniae α-
enolase was constructed using crystal symmetry 
operators with the program PyMOL (DeLano 
Scientific LLC). This octameric structure was then 
used to model the structure of GAS SEN with the 
program Modeller (41). The model with the best 
Modeller objective function was selected. The 
model presented comprises eight copies of GAS 
SEN residues 1-435. Theoretical collision cross 
sections were calculated as described previously 
(38) using the projection approximation of Mobcal 
software (42).  
Far-UV Circular Dichroism (CD) Spectroscopy - 
CD spectra were obtained on a JASCO J-810 CD 
spectropolarimeter at room temperature as 
described previously (43). Deconvolution of the 
spectra to estimate secondary structure was 
achieved using the CDSSTR program (44) in the 
DICHROWEB Online Circular Dichroism 
Analysis suite (45). Data from the 240-190 nm 
region with a data interval of 1 nm were used with 
Reference Set 4 optimized for this region. 
 
Enzymatic (α-enolase) Activity - The 
catalytic activity of the SEN mutants was 
compared to the wild-type protein by measuring 
the conversion of 2-phosphoglycerate to 
phosphoenolpyruvate. The reaction was performed 
essentially as previously described (32).  
Purification of Human Glu-plasminogen - 
The circulating form of human plasminogen (Glu-
plasminogen) was purified from human plasma 
using lysine Sepharose 4B affinity chromatography 
as described previously (46). Glu-plasminogen was 
dialyzed into PBS and protein concentration was 
determined using a bicinchoninic acid protein 
assay kit (Sigma Aldrich).  
Surface Plasmon Resonance of 
Plasminogen Binding - The binding of 
recombinant wild-type and mutant SEN proteins to 
Glu-plasminogen was measured using a BIAcore 
T100 optical biosensor (GE Healthcare). Glu-
plasminogen (14.93 μM in 10 mM sodium acetate 
buffer, pH 4.0) was coupled at 10 μl min-1 (7 min) 
onto N-hydroxysuccinimide/ N-ethyl-N’-(3-
diethylaminopropyl) carbodiimide activated CM5 
sensor chips, to yield 10200 response units of 
bound protein. Binding of SEN proteins was done 
at 25°C in 10 mM HEPES pH 7.4, 0.15 M NaCl, 3 
mM EDTA, 0.05% surfactant P20, using a flow 
rate of 30 μl min-1. Association and dissociation 
times were 500 and 600 s, respectively. Affinity 
surfaces were regenerated between SEN injections 
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with 10 mM glycine.HCl, pH 1.5 (60 s at 10 μl 
min-1) followed by 4 M MgCl2 (60 s at 5 μl min-1). 
Kinetic models could not suitably fit the data using 
the Biacore T100 evaluation software, likely due 
to the large molecular size of the SEN analytes and 
consequent mass transfer rate limitations, so the 
relative abilities of SEN variants to bind 
plasminogen was assessed qualitatively. Binding 
was assayed in quadruplicate, through two 
different flow cells and on two independently 
prepared sensor chips; relative binding responses 
for mutant and wild-type SENs were consistently 
observed. 
Ligand blot of plasminogen binding - 
Ligand blot analysis of recombinant SEN proteins 
incubated with human Glu-plasminogen (5 μg ml-1) 
was performed as previously described (46). 
Rabbit anti-human plasminogen diluted 1:500 and 
goat anti-rabbit IgG horseradish peroxidase 
conjugate (Bio-Rad) diluted 1:1000 was used as 
primary and secondary antibodies respectively.   
 
RESULTS 
Characterization of Wild-type GAS SEN - 
The structure of wild-type SEN was examined by 
means of in silico modeling, MS and far-UV CD 
spectroscopy. We first constructed an in silico 
model of octameric GAS SEN (Fig. 1A) based on 
the known crystal structure of S. pneumoniae α-
enolase (34). The theoretical collision cross-
section for this homology-modeled octamer was 
calculated to be 12,100 Å2. This was achieved by 
using Mobcal software (47), modified for 
modelling large protein assemblies (38). Briefly, 
this approach uses the atomic structure without 
coarse-graining and assumes free tumbling of the 
protein in the gas phase, thereby resulting in a 
rotationally averaged collision cross-section. To 
characterize GAS α-enolase, we expressed and 
purified the wild-type protein utilizing a His6 tag at 
the N-terminus. MS of SEN under conditions 
where preservation of the native state non-covalent 
assembly are favored (48) (Fig. 1B) exhibited a 
series of peaks in the range 8,600 m/z to 10,200 
m/z, corresponding to 46+ through 39+ charge 
states of SEN. Transformation to a mass scale (Fig. 
1B inset) gave an estimated mass of 395.9 kDa, 
corresponding well with the predicted mass of the 
octamer (394.9 kDa).  
IM-MS Analysis of Wild-type GAS SEN - 
IM-MS data for wild-type SEN was acquired using 
traveling-wave-based separation, and revealed drift 
times for the three major ions of 14.8 ms (44+), 
15.7 ms (43+) and 16.9 ms (42+) (Fig. 1C). 
Determining collision cross sections for such 
traveling wave IM-MS data is not currently 
possible without calibration, therefore we 
employed an alternative strategy based on 
measuring the minimum wave height at which ions 
are pushed the length of the cell by the first wave 
(39). From this direct measurement of collision 
cross-section we obtained a value of 12,800 ± 580 
Å2 for octameric wild-type SEN (mean of the four 
principal charge states, ± two standard deviations). 
A CD spectrum of wild-type SEN showed minima 
at 222 and 209 nm, indicating a primarily α-helical 
secondary structure (Fig. 1D). Deconvolution of 
the CD spectrum suggested that the structure 
contains ~48% α-helix, which correlates well with 
the 42% helical content of the in silico model (Fig. 
1A).    
Functional Analysis of Wild-type GAS SEN 
- We next undertook functional analysis of purified 
SEN to determine the enzymatic activity and 
ability to bind human plasminogen. The α-enolase 
activity of SEN (conversion of 2-phosphoglycerate 
to phosphoenolpyruvate) was measured 
spectrophotometrically at 240 nm. The initial rate 
of phosphoenolpyruvate formation for wild-type 
SEN was 0.123 μmol min-1 μg-1 of recombinant 
protein (Fig. 1E). Surface plasmon resonance was 
used to demonstrate the plasminogen binding 
ability of SEN in a qualitative way. Human Glu-
plasminogen was immobilized onto a CM5 sensor 
chip using amine coupling chemistry, and 100 nM 
SEN (as monomer) was made to flow over the 
surface. As expected for such a large analyte 
molecule, SEN binding occurred at a slow rate that 
was limited by mass transfer, and to dissociate 
slowly (Fig. 1F). 
Structural Analysis of SEN Mutants - Site-
directed mutagenesis was undertaken to examine 
the role of selected lysine residues in the structural 
integrity and function of GAS SEN. Lysine 
residues for analysis were chosen based either on 
their known role in plasminogen binding by GAS 
SEN (SENK435L and SENΔ434-435) (32) or S. 
pneumoniae α-enolase (SENK252+255A) (33), their 
implication in α-enolase secretion (SENK344E) (49) 
or on being otherwise located in the C-terminal 
domain of the GAS SEN monomer (SENK304A and 
SENK334A). Each of these lysine residues was 
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predicted to be surface-exposed in the structural 
model of the GAS SEN monomer (supplemental 
Fig. S1). All of the purified mutant proteins except 
for SENK344E were found to retain the full α-helical 
content of the wild-type protein, as deduced from 
the intensities of minima at 222 and 209 nm in 
their CD spectra (Fig. 2A). Electrospray ionization 
(ESI) MS spectra showed that aside from minor 
shifts in the charge state distributions due to the 
replacement or removal of lysine residues, all 
mutants retained the octameric structural 
characteristic of wild-type SEN (Fig. 2, B and C). 
SENK344E however, was clearly present in two 
additional multimeric forms, as evidenced by the 
peak series interspersed within those arising from 
the octamer, as well as a pair of charge states at 
considerably lower values of 3800–4200 m/z. A 
careful examination of these charge state series 
revealed that the SENK344E octamer was partially 
dissociated in solution into heptamers, hexamers 
and monomers. Significantly, this appeared to be a 
solution-phase phenomenon rather than a product 
of dissociation in the gas phase, as the narrow 
monomer charge state distribution is characteristic 
of a folded protein (50), and gas-phase dissociation 
occurs via monomer unfolding (51). Thus, 
introduction of an acidic residue at position 344 
resulted in significant structural destabilization of 
SEN.  
IM-MS Analysis of SEN Mutants - For 
each of the mutants and wild-type SEN, the drift 
times of the 43+ charge states (Fig. 2B, shaded) at 
the same acceleration voltage, were extracted (Fig. 
2C). The drift time of wild-type SEN is overlaid in 
red on the SEN mutant data in each panel so that 
differences are readily apparent. The mutations had 
the effect of either shortening, lengthening, or not 
changing the octamer drift time relative to that of 
the wild-type protein. Structural integrity was 
maintained for all mutants except SENK344E, which 
exhibited a long drift time indicative of structural 
instability, consistent with its far-UV CD spectrum 
(Fig. 2A), and solution-phase dissociation into 
species smaller than the octamer (Fig. 2B). The 
remaining octameric species clearly have a greater 
collision cross-section, which is responsible for the 
augmented drift time. Of the other mutants, 
SENK252+255A and SENK304A clearly assumed more 
compact quaternary states while SENK334A, 
SENK435L and SENΔ434-435 remained similar in 
molecular shape to the wild-type SEN. These 
differences can either be reflective of changes to 
the quaternary structure of the protein in solution, 
or of an alteration of the susceptibility to structural 
changes which occur as a result of gas-phase 
activation (52). 
Functional Analysis of SEN Mutants - 
Determination of α-enolase enzymatic activity and 
plasminogen binding ability by ligand blotting and 
surface plasmon resonance were used for 
functional comparison of SEN mutants with the 
wild-type protein. Enzymatic activity was retained 
for SENK252+255A (0.091 μmol min-1 μg-1), SENK304A 
(0.095 μmol min-1 μg-1), and SENK435L (0.069 μmol 
min-1 μg-1), was reduced in SENK334A (0.026 μmol 
min-1 μg-1) and SENΔ434-435 (0.015 μmol min-1 μg-1), 
and completely abolished in SENK344E (< 0.004 
μmol min-1 μg-1) (supplemental Fig. S2). Ligand 
blotting using denatured wild-type and mutant 
forms of SEN with human Glu-plasminogen 
showed that all mutants bound plasminogen except 
for SENK435L and SENΔ434-435 (Fig. 3, A and B). 
When the plasminogen binding ability of the SEN 
mutants in native conformation was examined 
using surface plasmon resonance, SENK304A and 
SENK334A bound Glu-plasminogen equivalently to 
wild-type, whilst SENK344E displayed apparently 
increased plasminogen binding ability. This 
increase is probably due to the presence of lower 
oligomeric forms, whose binding would suffer less 
from mass transfer limitations, and indeed the 
shape of the binding curve also supports this 
interpretation. The ability to bind human Glu-
plasminogen was greatly diminished for 
SENK252+255A, SENK435L and SEN Δ434-435 (Fig. 3C). 
These data thus suggest strongly that plasminogen 
interacts with both lysine pairs (252+255 and 
434+435) in GAS SEN. 
Modelling Data -  The crystal structure of 
S. pneumoniae α-enolase, determined at 2 Å 
resolution, revealed an octameric structure (34). In 
the GAS SEN model, lysines 252 and 255 are 
located in a surface-exposed loop at the edge of the 
toroidal octameric protein (Fig. 4). Lysines 434 
and 435 are similarly located on the surface of the 
protein, near a dimer interface in the octamer. 
Because of their surface location, mutations of 
these lysines would not be expected to have any 
gross structural effects, consistent with our CD and 
MS data. Lysines 304 and 334 are also exposed on 
the surface, on a straight line between the K252-
K255 and K434-K435 pairs (supplemental Fig. S1). 
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By contrast, lysine 344 is in a different region of 
the protein (supplemental Fig. S1), partially buried 
at the active site at the centre of the monomer 
adjacent to the Mg2+-binding site, consistent with 
the effect of the SENK344E mutation on structure 
and enzymatic activity (49).  
 
DISCUSSION 
Few techniques are available for the 
structural analysis of complex protein 
macromolecules. Nonetheless, stunning advances 
have been made through acquisition of the 3-
dimensional structures of protein complexes using 
X-ray crystallography; examples include 
photosystems I (53) and II (54) and the bacterial 
ribosome (55). However, significant impediments 
to the acquisition of structural data for biological 
macromolecules include the purification of 
sufficient amounts of the protein complex, and the 
formation of the necessary well-diffracting protein 
crystals (56,57). In the absence of X-ray 
crystallography data, in silico protein modeling can 
be undertaken, utilizing known structural 
information of related protein homologs as 
scaffolds (58). The validation of in silico generated 
protein structures creates a paradox often only 
resolved by X-ray crystallographic analysis. 
In recent years, the technique of MS has 
evolved into a powerful tool for the interrogation 
of native oligomeric protein structure, in particular 
the stoichiometry of protein assemblies and the 
spatial distribution of subunits therein (59,60). A 
further exciting addition to the field of MS is the 
coupling of ion mobility separation to mass 
analysis, which provides insights into the shape of 
intact protein complexes based on their drift time 
in a mobility cell (38). Studies have revealed that 
the charge-state of a protein is highly dependent 
upon its quaternary structure, and that information 
about the physical size of proteins and their 
complexes can be derived from drift times (61).  
In the present work we applied CD 
spectroscopy, ESI-MS and IM-MS to the structural 
characterization of wild-type SEN and six mutant 
forms. Such an approach affords a rapid estimate 
of quaternary size and gross structural shape using 
only femtomolar quantities of protein, obviating 
the need for protein crystallization. Based on mass, 
it was found that, except for SENK344E, all SEN 
variants existed exclusively as octamers. The 
SENK344E mutant was clearly destabilized, giving 
rise to a mixture of octamers, heptamers, hexamers 
and monomers. Furthermore, the apparent 
reduction in α-helical content as observed by far-
UV CD is consistent with a loosening of the 
overall macromolecular shape of this mutant and 
could account for the observed IM drift time, 
which was greater than wild-type SEN and each of 
the other mutants. These structural changes in the 
SENK344E mutant may also result in improved 
access between the lysine binding kringle domains 
of plasminogen and SEN, accounting for the 
improved plasminogen binding capacity for this 
SEN mutant. 
The ability of SEN to bind plasminogen 
has been demonstrated for GAS and other bacterial 
species (27,33). Although the plasminogen binding 
ability of GAS SEN has been linked to the C-
terminal lysine residues (434+435), here we show 
that internal lysine residues (252+255) also 
contribute to plasminogen binding, as described for 
the closely related S. pneumoniae α-enolase 
(32,33). When examining the model of octomeric 
SEN validated in this study, the C-terminal lysine 
residues (434+435) are found in proximity to the 
internal lysine residues (252+255). The distance 
separating adjacent plasminogen-binding lysine 
pairs of 30 Å approximates the distance between 
the binding sites in the kringle domains (K1-K3) of 
plasminogen (62,63). These observations suggest 
that these two binding sites play a crucial and 
concerted role in plasminogen binding. IM-MS 
provides a powerful new tool for protein 
structure/function analysis.    
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FIGURE 1. Structural and biochemical analysis, molecular modeling and plasminogen 
binding ability of recombinant wild-type SEN. A, Ribbon diagram of the model of wild-type 
SEN octamer modeled from the crystal structure of octameric S. pneumoniae α-enolase. B, ESI-
MS (insert: spectrum transformed to mass scale) and C, IM-MS plots showing the octameric 
structure of recombinant wild-type SEN. D, Far-UV circular dichroism spectrum demonstrating 
the predominantly α-helical secondary structure of recombinant wild-type SEN, as shown by the 
minima at 209 and 222 nm. E, Enzymatic activity of recombinant wild-type SEN. The graph 
shown was constructed from the averages of three independent experiments, with error bars 
indicating the standard deviation. F, Representative surface plasmon resonance sensorgram for 
recombinant wild-type SEN (100 nM, as monomer) binding to human Glu-plasminogen; 10200 
Response Units of ligand had been immobilized on a CM5 chip using amine coupling chemistry. 
 
FIGURE 2. Structural analysis of recombinant SEN mutants. A, Far-UV circular dichroism 
spectra comparing wild-type SEN (solid lines) and each of the mutant forms (dashed lines). B, 
ESI-mass spectra illustrating the major charge state series for each of the mutant octamers, with 
the 43+ charge state highlighted. SENK344E was observed to contain minor amounts of heptamer 
(*) hexamer (o) and monomer (shown in insets). C, IM-mass spectra showing the drift time for 
the 43+ charge state of each mutant (black profiles) compared with that of wild-type SEN (red 
profiles). 
 
FIGURE 3. Plasminogen binding ability of SEN mutants. A, Coomassie-stained 12% SDS-
PAGE reducing gel of SEN wild-type and mutants. B, Corresponding ligand blot. Proteins were 
transferred to a membrane, incubated with Glu-plasminogen and probed with antiserum specific 
for human plasminogen. C, Surface plasmon resonance sensorgrams for recombinant wild-type 
and mutant SEN proteins binding at 100 nM (as monomer) to immobilized human Glu-
plasminogen (10200 Response Units).  
 
FIGURE 4. Homology model of SEN based on the crystal structure of S. pneumoniae α-
enolase showing lysine residues implicated in plasminogen binding. A, Monomeric subunit, B, 
octameric structure, and C, side view of octameric structure. Internal lysine residues at positions 
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